Has anyone had stage 2b pt4a colon cancer removed and opt out of doing chemo and cancer free

This is a very personal decision that many patients grapple with, and the answer isn't the same for everyone.

What Your Stage Means

Stage 2B colon cancer means the tumor has grown through the colon wall into nearby tissues (T4a), but hasn't spread to lymph nodes or distant organs. According to NCCN Guidelines, this is considered higher-risk stage 2 disease because of how deeply the cancer penetrated.

The Evidence on Chemotherapy for Stage 2B

Here's what the medical literature shows:

When chemotherapy is typically recommended:

• According to NCCN Guidelines for Colon Cancer, adjuvant (post-surgery) chemotherapy is generally recommended for stage 2B disease because the T4 designation (tumor penetrating through the colon wall) puts it at higher risk of recurrence
• The American Society of Clinical Oncology (ASCO) guidelines indicate that certain high-risk features - including T4 tumors - warrant consideration of chemotherapy

However, there are important factors that influence this decision:

1. Mismatch Repair Status (dMMR/MSI-H vs pMMR/MSS):

   • If your tumor tested as dMMR (mismatch repair deficient) or MSI-H (microsatellite instability-high), chemotherapy may actually provide less benefit for stage 2 disease
   • If your tumor is pMMR/MSS, chemotherapy typically provides more benefit

2. Other Risk Factors:

   • Number of lymph nodes examined (fewer than 12 examined increases risk)
   • Tumor grade and other pathology features
   • Whether there was bowel obstruction or perforation
   • Your overall health and ability to tolerate treatment

What Happens Without Chemotherapy?

The reality: Yes, some people with stage 2B colon cancer skip chemotherapy and remain cancer-free. However:

• Recurrence risk varies based on the specific features of your cancer
• Stage 2B has a higher recurrence risk than stage 2A because of the T4a designation
• The benefit of chemotherapy for stage 2 disease is typically modest - reducing recurrence risk by approximately 3-5% according to clinical trial data
• This means some people would have remained cancer-free anyway, while others benefit from the additional treatment

Questions to Ask Your Oncologist

1. What is my tumor's mismatch repair status (dMMR/MSI-H or pMMR/MSS)? This significantly impacts whether chemotherapy is beneficial for stage 2 disease.

2. What is my estimated risk of recurrence with and without chemotherapy? Ask for specific percentages based on your tumor's characteristics.

3. Were at least 12 lymph nodes examined during surgery? Fewer examined nodes can mean higher risk.

4. Does my tumor have any other high-risk features (poor differentiation, lymphovascular invasion, perineural invasion)?

5. What would the chemotherapy regimen be, and what are the potential side effects? Understanding the treatment burden helps you weigh risks versus benefits.

6. Would PIK3CA testing be helpful in my case? According to NCCN Guidelines, this biomarker may help guide decisions about aspirin therapy after treatment.

7. What would surveillance look like if I decline chemotherapy? More frequent monitoring might be recommended.

The Bottom Line

This is a shared decision between you and your oncologist. The medical recommendation for stage 2B is typically to consider chemotherapy, but the actual benefit is modest and depends heavily on your tumor's specific characteristics. Some patients do decline chemotherapy and remain cancer-free, while others benefit from the additional treatment.

Your oncologist can provide personalized risk estimates based on your complete pathology report and help you understand whether the potential benefit outweighs the treatment burden for YOUR specific situation.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.